N,N'-[1,3,4-Oxadiazole-2,5-diyldi(4,1-phenylene)]dibenzamide | 92135-07-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N,N'-[1,3,4-Oxadiazole-2,5-diyldi(4,1-phenylene)]dibenzamide
• 英文别名: N-[4-[5-(4-benzamidophenyl)-1,3,4-oxadiazol-2-yl]phenyl]benzamide
• CAS: 92135-07-4
• 化学式: C₂₈H₂₀N₄O₃
• 分子量: 460.5
• InChiKey: OLTOQZCZGHNNGE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  35
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  97.1
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• [EN] HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES<br/>[FR] COMPOSÉS À PETITES MOLÉCULES MIMÉTIQUES DES FACTEURS DE CROISSANCE HÉMATOPOÏÉTIQUE ET LEURS UTILISATIONS
  申请人：LIGAND PHARM INC

  公开号：WO2011046954A1

  公开（公告）日：2011-04-21

  The present embodiments relate to compounds with physiological effects, such as the activation of hematopoietic growth factor receptors. The present embodiments also relate to use of the compounds to treat a variety of conditions, diseases and ailments such as hematopoietic conditions and disorders.

  目前的实施例涉及具有生理效应的化合物，例如激活造血生长因子受体。目前的实施例还涉及利用这些化合物来治疗各种疾病、疾病和疾患，如造血状况和疾病。
• HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES
  申请人：Zhi Lin

  公开号：US20120295904A1

  公开（公告）日：2012-11-22

  The present embodiments relate to compounds with physiological effects, such as the activation of hematopoietic growth factor receptors. The present embodiments also relate to use of the compounds to treat a variety of conditions, diseases and ailments such as hematopoietic conditions and disorders.

  本实施例涉及具有生理效应的化合物，例如激活造血生长因子受体。本实施例还涉及使用这些化合物来治疗各种状况、疾病和疾病，例如造血系统状况和疾病。
• US9144557B2
  申请人：——

  公开号：US9144557B2

  公开（公告）日：2015-09-29
• US9622991B2
  申请人：——

  公开号：US9622991B2

  公开（公告）日：2017-04-18
• [EN] USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS<br/>[FR] UTILISATION DE MIMÉTIQUES D'UN FACTEUR DE CROISSANCE HÉMATOPOÏÉTIQUE
  申请人：LIGAND PHARM INC

  公开号：WO2012068406A2

  公开（公告）日：2012-05-24

  The present invention relates to uses of small molecule mimetics of hematopoietic growth factors. In particular the present invention relates to uses of small molecule mimetics of erythropoietin.